Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis.

Weyand AC, Grzegorski SJ, Rost MS, Lavik KI, Ferguson AC, Menegatti M, Richter CE, Asselta R, Duga S, Peyvandi F, Shavit JA.

Blood Adv. 2019 Jun 11;3(11):1670-1680. doi: 10.1182/bloodadvances.2018029066.

2.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.

Oldenburg J, Hay CRM, Jiménez-Yuste V, Peyvandi F, Schved JF, Szamosi J, Winding B, Lethagen S.

BMJ Open. 2019 May 30;9(5):e028012. doi: 10.1136/bmjopen-2018-028012.

3.

Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.

Novembrino C, Boscolo Anzoletti M, Mancuso ME, Shinohara S, Peyvandi F.

Haemophilia. 2019 May;25(3):521-526. doi: 10.1111/hae.13746. Epub 2019 May 2.

PMID:
31044485
4.

Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.

Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F.

Haematologica. 2019 Mar 28. pii: haematol.2018.215129. doi: 10.3324/haematol.2018.215129. [Epub ahead of print]

5.

Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry.

Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B, Mikovic D, Peyvandi F; Italian Group of TTP Investigators.

Thromb Haemost. 2019 May;119(5):695-704. doi: 10.1055/s-0039-1679907. Epub 2019 Mar 12.

PMID:
30861548
6.

Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study.

Maino A, Algra A, Peyvandi F, Rosendaal FR, Siegerink B.

BMC Cardiovasc Disord. 2019 Mar 7;19(1):55. doi: 10.1186/s12872-019-1040-4.

7.

Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects.

Gorski MM, Lecchi A, Femia EA, La Marca S, Cairo A, Pappalardo E, Lotta LA, Artoni A, Peyvandi F.

Haematologica. 2019 Feb 28. pii: haematol.2018.204990. doi: 10.3324/haematol.2018.204990. [Epub ahead of print]

8.

Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency.

Paraboschi EM, Menegatti M, Peyvandi F, Duga S, Asselta R.

Int J Mol Sci. 2019 Feb 20;20(4). pii: E910. doi: 10.3390/ijms20040910.

9.

Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura.

Ferrari B, Cairo A, Pagliari MT, Mancini I, Arcudi S, Peyvandi F.

J Thromb Haemost. 2019 Apr;17(4):666-669. doi: 10.1111/jth.14409. Epub 2019 Mar 6.

PMID:
30762934
10.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.

Blood Transfus. 2019 Feb 4:1-8. doi: 10.2450/2019.0183-18. [Epub ahead of print]

11.

Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Farrokhi Moshai E, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jan 31. pii: haematol.2018.212001. doi: 10.3324/haematol.2018.212001. [Epub ahead of print]

12.

Body mass index reduction improves the baseline procoagulant imbalance of obese subjects.

Tripodi A, Primignani M, Badiali S, de Ruberto F, Granelli P, Tosetti G, Clerici M, Padovan L, Chantarangkul V, Scalambrino E, Peyvandi F.

J Thromb Thrombolysis. 2019 Jul;48(1):52-60. doi: 10.1007/s11239-019-01818-9.

PMID:
30701462
13.

Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.

Arcudi S, Ferrari B, Pontiggia S, Tufano A, Artoni A, Mancini I, Peyvandi F.

J Thromb Haemost. 2019 Mar;17(3):492-498. doi: 10.1111/jth.14381. Epub 2019 Feb 25.

PMID:
30629316
14.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

PMID:
30625070
15.

Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.

Tripodi A, Chantarangkul V, Clerici M, Bader R, Anzoletti MB, Peyvandi F, Santagostino EM; PredicTGA Collaborators.

Thromb Res. 2019 Feb;174:84-87. doi: 10.1016/j.thromres.2018.12.007. Epub 2018 Dec 6. No abstract available.

PMID:
30579150
16.

Treatment of rare factor deficiencies other than hemophilia.

Menegatti M, Peyvandi F.

Blood. 2019 Jan 31;133(5):415-424. doi: 10.1182/blood-2018-06-820738. Epub 2018 Dec 17. Review.

PMID:
30559262
17.

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2019 Jun;104(6):1268-1276. doi: 10.3324/haematol.2018.205666. Epub 2018 Dec 6.

18.

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S.

Haemophilia. 2019 Jan;25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14.

19.

Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem® device.

Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Biliou S, Peyvandi F, Tripodi A.

Thromb Res. 2018 Dec;172:139-141. doi: 10.1016/j.thromres.2018.10.030. Epub 2018 Oct 31. No abstract available.

PMID:
30412836
20.

Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus.

Stufano F, Baronciani L, Biguzzi E, Cozzi G, Colpani P, Chisini M, Peyvandi F.

Haemophilia. 2019 Jan;25(1):e30-e32. doi: 10.1111/hae.13626. Epub 2018 Nov 8. No abstract available.

21.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

22.

Hemostatic abnormalities in patients with Ehlers-Danlos syndrome.

Artoni A, Bassotti A, Abbattista M, Marinelli B, Lecchi A, Gianniello F, Clerici M, Bucciarelli P, La Marca S, Peyvandi F, Martinelli I.

J Thromb Haemost. 2018 Dec;16(12):2425-2431. doi: 10.1111/jth.14310. Epub 2018 Nov 8.

PMID:
30312027
23.

Advances in the Treatment of Hemophilia: Implications for Laboratory Testing.

Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F.

Clin Chem. 2019 Feb;65(2):254-262. doi: 10.1373/clinchem.2017.284356. Epub 2018 Oct 3. Review.

PMID:
30282700
24.

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Roose E, Vidarsson G, Kangro K, Verhagen OJHM, Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K.

Thromb Haemost. 2018 Oct;118(10):1729-1742. doi: 10.1055/s-0038-1669459. Epub 2018 Sep 20.

25.

Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes.

de Haan HG, van Hylckama Vlieg A, Lotta LA, Gorski MM, Bucciarelli P, Martinelli I, Baglin TP, Peyvandi F, Rosendaal FR; INVENT consortium.

J Thromb Haemost. 2018 Dec;16(12):2432-2441. doi: 10.1111/jth.14279. Epub 2018 Oct 16.

26.

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls.

Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A.

Haemophilia. 2018 Sep;24(5):726-732. doi: 10.1111/hae.13595. Epub 2018 Aug 16.

PMID:
30112863
27.

Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.

Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.

Res Pract Thromb Haemost. 2018 Apr 12;2(3):407-428. doi: 10.1002/rth2.12095. eCollection 2018 Jul. Review.

28.

Product type and other environmental risk factors for inhibitor development in severe hemophilia A.

Peyvandi F, Garagiola I.

Res Pract Thromb Haemost. 2018 Apr 10;2(2):220-227. doi: 10.1002/rth2.12094. eCollection 2018 Apr.

29.

Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation.

Pagliari MT, Baronciani L, Stufano F, Colpani P, Siboni SM, Peyvandi F.

Haemophilia. 2018 Jul;24(4):e263-e266. doi: 10.1111/hae.13532. Epub 2018 Jul 25. No abstract available.

PMID:
30044032
30.

Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis.

Gorski MM, de Haan HG, Mancini I, Lotta LA, Bucciarelli P, Passamonti SM, Cairo A, Pappalardo E, van Hylckama Vlieg A, Martinelli I, Rosendaal FR, Peyvandi F.

Thromb Res. 2018 Sep;169:76-81. doi: 10.1016/j.thromres.2018.06.011. Epub 2018 Jun 15.

PMID:
30029070
31.

How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues.

Tripodi A, Braham S, Scimeca B, Moia M, Peyvandi F.

Pol Arch Intern Med. 2018 Jun 29;128(6):379-385. doi: 10.20452/pamw.4287. Epub 2018 Jun 29.

32.

Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.

Stufano F, Boscarino M, Bucciarelli P, Baronciani L, Maino A, Cozzi G, Peyvandi F.

Semin Thromb Hemost. 2019 Feb;45(1):36-42. doi: 10.1055/s-0038-1660481. Epub 2018 Jun 18.

PMID:
29913537
33.

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Szederjesi A, Baronciani L, Budde U, Castaman G, Lawrie AS, Liu Y, Montgomery R, Peyvandi F, Schneppenheim R, Várkonyi A, Patzke J, Bodó I.

J Thromb Haemost. 2018 Jun 13. doi: 10.1111/jth.14206. [Epub ahead of print]

PMID:
29897666
34.

Risk factors for inhibitor development in severe hemophilia a.

Garagiola I, Palla R, Peyvandi F.

Thromb Res. 2018 Aug;168:20-27. doi: 10.1016/j.thromres.2018.05.027. Epub 2018 May 25. Review.

PMID:
29879570
35.

Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.

Peyvandi F, Palla R, Franchi C, Nobili A, Rosendaal FR, Mannucci PM.

Haemophilia. 2018 Jul;24(4):e266-e268. doi: 10.1111/hae.13535. Epub 2018 Jun 5. No abstract available.

PMID:
29869363
36.

Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss.

Al-Khabori M, Pathare A, Menegatti M, Peyvandi F.

J Thromb Haemost. 2018 Jun;16(6):1052-1054. doi: 10.1111/jth.14126. Epub 2018 May 13.

PMID:
29665207
37.

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards.

Proietti M, Antoniazzi S, Monzani V, Santalucia P, Franchi C; SIM-AF Investigators, Fenoglio LM, Melchio R, Fabris F, Sartori MT, Manfredini R, De Giorgi A, Fabbian F, Biolo G, Zanetti M, Altamura N, Sabbà C, Suppressa P, Bandiera F, Usai C, Murialdo G, Fezza F, Marra A, Castelli F, Cattaneo F, Beccati V, di Minno G, Tufano A, Contaldi P, Lupattelli G, Bianconi V, Cappellini D, Hu C, Minonzio F, Fargion S, Burdick L, Francione P, Peyvandi F, Rossio R, Colombo G, Monzani V, Ceriani G, Lucchi T, Brignolo B, Manfellotto D, Caridi I, Corazza GR, Miceli E, Padula D, Fraternale G, Guasti L, Squizzato A, Maresca A, Liberato NL, Tognin T, Rozzini R, Bellucci FB, Muscaritoli M, Molfino A, Petrillo E, Dore M, Mete F, Gino M, Franceschi F, Gabrielli M, Perticone F, Perticone M, Bertolotti M, Mussi C, Borghi C, Strocchi E, Durazzo M, Fornengo P, Dallegri F, Ottonello LC, Salam K, Caserza L, Barbagallo M, Di Bella G, Annoni G, Bruni AA, Odetti P, Nencioni A, Monacelli F, Napolitano A, Brucato A, Valenti A, Castellino P, Zanoli L, Mazzeo M.

Eur J Intern Med. 2018 Jun;52:e12-e14. doi: 10.1016/j.ejim.2018.04.006. Epub 2018 Apr 12. No abstract available.

PMID:
29657108
38.

"In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate.

Bulato C, Novembrino C, Anzoletti MB, Spiezia L, Gavasso S, Berbenni C, Tagariello G, Farina C, Nardini I, Campello E, Peyvandi F, Simioni P.

Haemophilia. 2018 Jul;24(4):648-656. doi: 10.1111/hae.13465. Epub 2018 Mar 26.

PMID:
29578313
39.

An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia.

Depetri F, Cugno M, Graziadei G, Di Pierro E, Granata F, Peyvandi F, Cappellini MD.

Intern Emerg Med. 2018 Dec;13(8):1233-1238. doi: 10.1007/s11739-018-1826-x. Epub 2018 Mar 17. No abstract available.

PMID:
29550908
40.

First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries.

Pierce GF, Haffar A, Ampartzidis G, Peyvandi F, Diop S, El-Ekiaby M, van den Berg HM.

Haemophilia. 2018 Mar;24(2):229-235. doi: 10.1111/hae.13409. Epub 2018 Mar 14.

41.

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban.

Martinelli I, Abbattista M, Bucciarelli P, Tripodi A, Artoni A, Gianniello F, Novembrino C, Peyvandi F.

Haematologica. 2018 Jul;103(7):e315-e317. doi: 10.3324/haematol.2017.185132. Epub 2018 Mar 8. No abstract available.

42.

Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Mariani S, Trisolini SM, Capria S, Moleti ML, Chisini M, Ferrazza G, Bafti MS, Limongiello MA, Miulli E, Peyvandi F, Foà R, Testi AM.

Haematologica. 2018 Mar;103(3):e138-e140. doi: 10.3324/haematol.2017.185363. No abstract available.

43.

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.

Spena S, Garagiola I, Cannavò A, Mortarino M, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET Study Group.

J Thromb Haemost. 2018 Apr;16(4):778-790. doi: 10.1111/jth.13961. Epub 2018 Mar 23.

PMID:
29399993
44.

Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".

Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM.

Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22. No abstract available.

45.

Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.

Reda G, Cassin R, Artoni A, Fattizzo B, Lecchi A, La Marca S, Bucciarelli P, Levati GV, Peyvandi F, Cortelezzi A.

Br J Haematol. 2018 Dec;183(5):825-828. doi: 10.1111/bjh.15052. Epub 2018 Jan 7. No abstract available.

PMID:
29315493
46.

Acquired Von Willebrand syndrome and response to desmopressin.

Biguzzi E, Siboni SM, Peyvandi F.

Haemophilia. 2018 Jan;24(1):e25-e28. doi: 10.1111/hae.13382. Epub 2017 Dec 13. No abstract available.

PMID:
29239101
47.

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.

Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz BA, Knaub S, Peyvandi F.

J Thromb Haemost. 2018 Feb;16(2):253-261. doi: 10.1111/jth.13923. Epub 2018 Jan 22.

48.

Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.

Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Schwartz BA, Solomon C, Knaub S, Peyvandi F.

Transfusion. 2018 Feb;58(2):413-422. doi: 10.1111/trf.14421. Epub 2017 Nov 30.

49.

Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review
.

Rossio R, Arcudi S, Peyvandi F, Piconi S.

Int J Clin Pharmacol Ther. 2018 Feb;56(2):86-89. doi: 10.5414/CP203084. Review.

PMID:
29191263
50.

Molecular investigation of 41 patients affected by coagulation factor XI deficiency.

Rimoldi V, Paraboschi EM, Menegatti M, Peyvandi F, Salomon O, Duga S, Asselta R.

Haemophilia. 2018 Mar;24(2):e50-e55. doi: 10.1111/hae.13378. Epub 2017 Nov 27. No abstract available.

PMID:
29178608

Supplemental Content

Loading ...
Support Center